药明生物发布2025年度可持续发展报告，助力可持续业务增长与普惠健康发展

在可持续发展战略的系统指引下，公司构建了稳健的企业治理架构和清晰的管理流程。对标联合国可持续发展目标，公司设定了科学、可衡量的ESG目标矩阵，并制定了完善的实施路线图，通过定期追踪绩效推动持续改进。

药明生物坚持与各利益相关方进行开放透明的沟通，致力于构建长期互信的合作伙伴关系。作为制药供应链组织（PSCI）积极参与者，公司全面遵循PSCI原则，并携手全球供应商伙伴在商业道德、人权与劳工、健康与安全、环境及管理体系等关键领域推动负责任实践。2025年，公司获得ISO 20400可持续采购体系认证，进一步夯实供应链韧性基础；公司建立健全覆盖全流程的知识产权、商业秘密与数据隐私保护体系，形成制度、技术与管理多重防线，确保各项保护措施落实到位；同时，公司持续强化企业韧性与风险管理能力，顺利通过ISO 22301业务连续性管理体系认证，为全球运营与公共卫生响应提供稳定保障。

药明生物高度重视全球员工的贡献，人才队伍专业能力突出、背景多元，来自51个国家和地区。公司积极支持女性在科学、技术、工程和数学（STEM）领域的职业发展，目前公司STEM岗位女性占比达54%，显著高于行业平均水平。

同时，社区回馈是公司创造正向社会价值的重要组成部分。2025年，公司员工在本地社区累计志愿服务时长超过12000小时，持续为社区发展贡献力量。

此外，药明生物积极推动员工价值与社区价值的深度共生：弘扬志愿服务精神，组织员工参与公益行动，切实发挥企业责任，推动社会韧性建设。

药明生物始终致力于缩短药物“从分子到患者”的时间，通过构建全球化、大规模的端到端一体化CRDMO平台，提升创新生物药的可及性与可负担性，为推动全球医疗公平、改善公共健康贡献长期价值。

依托自身核心技术能力，药明生物积极响应全球公共卫生事件，赋能合作伙伴推进创新疗法开发，惠及全球病患。2025年，药明生物与巴西布坦坦研究所及布坦坦基金会达成合作，助力扩大登革热疫苗（Butantan-DV）商业化生产规模，持续提升当地公共卫生防护能力。公司相关工厂已获得巴西国家卫生监督管理局（ANVISA）颁发的GMP认证。

在罕见病领域，截至2025年底，公司平台承载23个罕见病项目，已赋能三款罕见病药物上市。2025年5月，合作伙伴北海康成宣布其创新罕见病治疗产品注射用维拉苷酶β（商品名：戈芮宁®）获中国国家药品监督管理局（NMPA）批准上市，标志着双方在推动罕见病创新疗法方面取得重要突破。

此外，公司关注社区健康支持，通过应急救援、基层医疗重建、疾病救助与社区健康扶助等多类项目，持续支持地方卫生系统建设，延伸医疗可及至「最后一公里」。

从全球公共卫生响应到个体生命关怀，药明生物以平台技术能力、全球韧性网络、世界级质量体系，加速提升全球医疗可及性，守护全球健康。

药明生物不断强化在气候变化应对、资源高效利用、循环经济实践、生态系统保护及绿色创新等方面的环境治理与领导力。

2025年，药明生物全新温室气体减排目标矩阵获科学碳目标倡议SBTi认证。同时，公司实现了以2019年为基准降低30%用水密度的既定目标，并在10个基地实施卓越水管理计划。为推动行业可持续发展，公司发布《药明生物Green CRDMO白皮书》，系统展示了生物药绿色研发与生产实践，以及绿色运营所带来的显著节能减排成果。

为持续提升卓越运营水平，药明生物将WBS精益管理体系与可持续发展战略进行深度融合。2025年，超过95%的WBS改善项目取得了ESG成效，在降低碳排放、减少水资源消耗、实现废弃物减量等方面发挥了积极作用。

药明生物在可持续发展领域的持续投入，获得多家国际权威ESG评级机构认可，包括MSCI ESG最高AAA评级、EcoVadis铂金勋章、入选道琼斯最佳指数（原道琼斯可持续发展指数）、CDP气候变化、水安全及供应商合作评估“A 级榜单”、Sustainalytics最高“风险可忽略”评级、入选富时社会责任指数、ISS ESG“最佳”评级，以及入选恒生可持续发展企业基准指数，充分彰显了公司在可持续发展领域的卓越表现。

陈智胜博士表示：“展望未来，药明生物将继续保持强劲增长势头，凭借领先的生物药研究、开发及生产能力，驱动公司业务实现加速增长。以可持续发展为公司创新、运营和增长的核心，我们将持续赋能全球客户，推动生物药创新疗法惠及广大病患，为所有利益相关方创造长期价值，共同迈向健康未来。”

查看完整药明生物2025年度可持续发展报告，请复制到浏览器打开：https://www.wuxibiologics.com.cn/wp-content/uploads/C_898490_WUXI-BIO_ESG2025_0429_1652_ESS.pdf

Guided by a comprehensive sustainability strategy, WuXi Biologics has put in place robust corporate governance structures and well-defined management processes. In alignment with the United Nations Sustainable Development Goals, the company has established science-based, measurable ESG target matrix supported by a detailed roadmap to monitor performance and enable continuous improvement.

WuXi Biologics is committed to open and transparent engagement with stakeholders, and to building long-term, trusted partnerships. As an active participant of the Pharmaceutical Supply Chain Initiative (PSCI), the Company adheres to PSCI principles across Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems, and collaborates with global suppliers to promote responsible practices. In 2025, WuXi Biologics achieved ISO 20400 Sustainable Procurement certification, further strengthening supply chain resilience. The Company has established a comprehensive, end-to-end framework to protect intellectual property, trade secrets, and data privacy through institutional, technical, and managerial safeguards, ensuring effective implementation across operations. Meanwhile, the Company continues to enhance its business resilience and risk management capabilities by achieving ISO 22301 Business Continuity Management System certification, supporting stable global operations and public health responses.

WuXi Biologics highly values the contributions of its global workforce and is proud of its diverse, highly professional talent base representing 51 nationalities. The Company actively supports the career development of women in Science, Technology, Engineering and Mathematics (STEM), with 54% of STEM positions held by female employees, significantly exceeding the industry average.

Community engagement remains a vital component of WuXi Biologics' positive social impact. In 2025, employees contributed over 12,000 volunteer hours in local communities. The Company also promoted closer alignment between employee engagement and community needs by mobilizing volunteer efforts in community initiatives, contributing to greater social resilience.

By shortening the timeline from molecules to patients, we enable innovative biologics to reach patients faster, at greater scale, and with consistent quality — driving equitable access to healthcare worldwide. Through the establishment of a global, large‑scale, end‑to‑end integrated CRDMO platform, the Company continues to create long‑term value in support of global healthcare equity and improved public health outcomes.

Building on its core technology capabilities, WuXi Biologics actively responds to global public health needs by empowering partners to accelerate the development and manufacturing of innovative therapies for patients around the world. In 2025, the Company has partnered with Instituto Butantan and Fundação Butantan in Brazil to support the scaled commercial manufacturing for the dengue vaccine Butantan-DV, contributing to the strengthening of local public health preparedness. The fill-and-finish facility serving this project has received GMP certification from the Brazilian Health Regulatory Agency (ANVISA).

Rare diseases remain a key focus of the Company's platform‑based innovation. As of the end of 2025, there were 23 rare disease projects on our platform. In May 2025, partner CANbridge Pharmaceuticals received approval from the National Medical Products Administration (NMPA) for velaglucerase-beta for injection (Gaurunning®), marking a significant milestone in advancing innovative rare disease therapies through collaboration.

In addition, the Company is committed to supporting community health through a range of initiatives, including emergency relief, primary healthcare rebuilding, disease assistance, and community health programs, continuously strengthening local healthcare systems and extending healthcare accessibility to the "last mile".

From global public health response to individual care, WuXi Biologics leverages its integrated technology platforms, resilient global network and unified world‑class quality systems to continuously enhance healthcare accessibility, safeguarding the health and well-being of patients worldwide.

The Company continues to enhance environmental stewardship across climate change mitigation, resource efficiency, circular economy practices, ecosystem protection and green innovation.

In 2025, WuXi Biologics introduced a new and ambitious greenhouse gas emission target matrix that was validated by the Science Based Targets initiative (SBTi). The Company also achieved its water management target of reducing water consumption intensity by 30% from the base year 2019 and rolled out its Water Excellence Stewardship program across 10 sites. To support broader industry sustainability, WuXi Biologics published the Green CRDMO White Paper, detailing its green research, development and manufacturing practices, and highlighting energy-saving and carbon-reduction outcomes enabled by green operations.

To drive continuous improvement for operational excellence, WuXi Biologics Business System (WBS) applies lean management principles and integrates with sustainability strategy. In 2025, over 95% of WBS Kaizen projects generated measurable ESG benefits, including reductions in carbon emission, water consumption and waste generation.

WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies. These recognitions include an MSCI AAA ESG rating; an EcoVadis Platinum Medal; inclusion in the Dow Jones Best-in-Class Indices (formerly Dow Jones Sustainability Indices); CDP "A List" status for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk ESG rating by Sustainalytics; inclusion in the FTSE4Good Index Series; a "Prime" designation from ISS ESG Corporate Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

Dr. Chris Chen commented, “Looking ahead to 2026 and beyond, we will build on our strong momentum to accelerate growth, driven by robust research, development and manufacturing capabilities. With sustainability at the core of how we innovate, operate, and grow, WuXi Biologics will continue to empower global clients to bring life-changing therapies to patients worldwide, while delivering long-term value and shared success for all stakeholders in pursuit of a healthier future.”